The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial
Stephen Phillips, Joanna M. Wardlaw(UK Dementia Research Institute), Gordon Murray(University of Edinburgh), Gord Gubitz(Dalhousie University), Graeme J. Hankey, Adam Kobayashi, Peter Sandercock(University of Edinburgh), Veronica Murray(Karolinska Institutet), Karen Innes(University of Aberdeen), Karl Matz, Martin Dennis(Institute of Technology Assessment), Richard I. Lindley(Westmead Hospital), Anna Członkowska, G.S. Venables, Manuel Correia, Phillippe Lyrer(Dalhousie University), Stefano Ricci, André Peeters, Geoff Cohen(University of Edinburgh), Eivind Berge(Oslo University Hospital), Karsten Bruins Slot
Cited by 1,190
Related Papers
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
|New England Journal of Medicine|2011|9.4k
Health effects of dietary risks in 195 countries, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
|The Lancet|2019|5.7k
Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration
|The Lancet Neurology|2013|5.4k